GET DAILY SIGNALSInspire Medical Systems (INSP) +17% Surge After Q3 Earnings Beat and Raised Guidance
Key Takeaways
- Inspire Medical Systems (INSP) reported third-quarter 2025 revenue of $224.5 million, up 10% from $203.2 million in the prior-year period.
- Adjusted earnings per share (EPS) came in at $0.38, far ahead of the consensus estimate for a loss of $0.19 per share.
- Diluted net income per share was $0.34, down from $0.60 a year earlier, reflecting higher operating expenses tied to patient marketing and corporate costs.
- Full-year 2025 revenue guidance was reaffirmed at $900 million to $910 million, while EPS guidance was raised to $0.90 to $1.00 from a prior range of $0.40 to $0.50.
- Gross margin improved to 85.8% from 84.1%, helped by higher sales volume and a favorable mix of the newer Inspire V system.
- For deeper insight into INSP, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- You can also explore Trending AI Robots for automated, AI-driven trading ideas across the market.
Earnings Context and Why It Matters
Inspire Medical Systems is a leader in implantable neurostimulation therapy for obstructive sleep apnea (OSA), offering an alternative to traditional CPAP treatment. The third quarter carried added significance because the company was in the midst of transitioning its installed base to its next-generation Inspire V system. Investors were watching whether that product transition would disrupt revenue momentum or reinforce the company's competitive position. The quarter also unfolded against a backdrop of rising interest in GLP-1 weight-loss medications, which have fueled debate about their potential impact on the OSA patient population. With the stock trading well below its historical highs heading into the report, this earnings release served as a key test of both growth durability and management's execution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Inspire Medical Systems reported third-quarter 2025 revenue of $224.5 million, a 10% increase from $203.2 million in the same period last year. U.S. revenue rose 9% to $214.4 million, while revenue outside the U.S. climbed 37% to $10.1 million. Adjusted EPS of $0.38 comfortably beat the consensus estimate of a $0.19 loss, while GAAP diluted EPS came in at $0.34, down from $0.60 a year earlier. Gross margin expanded to 85.8% from 84.1%, reflecting higher sales volume and a greater mix of the Inspire V system. Operating income declined to $9.6 million from $14.3 million, as operating expenses increased 17% year over year, driven largely by patient marketing and general corporate costs.
Management reaffirmed full-year 2025 revenue guidance of $900 million to $910 million, implying 12% to 13% growth, and raised its diluted net income per share outlook to $0.90 to $1.00, up sharply from a previous range of $0.40 to $0.50. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was $44.0 million, roughly in line with $44.5 million a year earlier.
Market Reaction and Investor Sentiment
Investors responded enthusiastically to the beat-and-raise quarter. Shares of INSP jumped roughly 17% following the report, signaling that the market viewed the EPS outperformance and upgraded full-year earnings guidance as evidence of stabilizing profitability. The positive reaction came even as several analysts trimmed their price targets in the days after the announcement, reflecting broader valuation recalibration rather than a change in fundamental conviction. Sentiment appeared most encouraged by the company's reaffirmed revenue outlook and its progress on the Inspire V rollout, with more than 98% of physician training complete and over 75% of centers implanting the new system.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be focused on how the Inspire V transition progresses through the remainder of 2025 and into 2026. Management indicated that most centers should complete the switch by year-end, with a smaller number continuing to use the legacy Inspire IV system for economic reasons. A smooth transition is important because the newer device carries a lower cost of goods sold, which has helped support gross margin.
Another key theme is the interplay between Inspire therapy and GLP-1 medications, a class of drugs increasingly used to treat obesity and, in some cases, obstructive sleep apnea. The company's survey work suggests these drugs are bringing more patients into sleep clinics, which management sees as an opportunity to expand the pool of patients eligible for Inspire therapy over time. Monitoring patient flow and provider capacity will be central to the growth story.
Finally, investors should track operating expense discipline and upcoming Medicare reimbursement changes. Management has signaled that operating expenses should align more closely with revenue growth, while proposed increases to hospital and ambulatory surgical center reimbursement for the company's implant procedure are expected to take effect in January 2026. Combined with formal 2026 guidance expected in January, these factors will shape how the market evaluates the company's path toward sustained, profitable growth.
Exploring AI Tools for Stock Analysis
In my own process, I regularly rely on Tickeron’s AI Screener to quickly scan for stocks with similar technical setups or fundamental profiles. It allows me to filter by industry, performance metrics, and AI signals, which helps put individual earnings reports like this one into broader context without spending hours on manual research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INSP sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for INSP moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +3.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSP advanced for three days, in 229 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INSP as a result. In 65 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for INSP turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
INSP moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. INSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.385) is normal, around the industry mean (4.204). P/E Ratio (14.837) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.375) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of implantable neurostimulation systems to treat obstructive sleep apnea
Industry MedicalNursingServices
Advertisement